Due to new criteria, 18 stocks, including Abbott India and Metropolis Health, may be removed from the F&O segment, while 79 stocks are potential entrants. Final decisions rest with SEBI, with a review expected in December 2024.
| Subscribe To Our Free Newsletter |
